Management Strategies for a Better Outcome in Unstab

Clinical Cardiology 21, 314-322 DOI: 10.1002/clc.4960210504

Citation Report

#	Article	IF	CITATIONS
1	Treatment of patients with acute (unstable) symptoms due to coronary artery disease. Clinical Cardiology, 1998, 21, 539-541.	0.7	1
2	New trials of LMW heparins — light and heavy weight as good on short but what about longer distances?. European Heart Journal, 1999, 20, 1522-1524.	1.0	1
3	New antithrombotic treatment in unstable coronary syndrome—for whom?. Lancet, The, 1999, 353, 423-424.	6.3	4
4	Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet, The, 1999, 354, 708-715.	6.3	1,219
5	Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet, The, 1999, 354, 701-707.	6.3	374
6	Low-Molecular-Weight Heparins in Coronary Thrombosis: Today and Tomorrow. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1999, 29, 32-37.	0.5	2
7	Targeting treatment for optimal outcome. Clinical Cardiology, 2000, 23, 18-22.	0.7	22
9	The acute coronary syndromes: advances in medical and interventional management. Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine, 2000, 11, 3-12.	0.1	1
10	Cardiac markers into the new millennium. Annals of Clinical Biochemistry, 2000, 37, 109-113.	0.8	13
11	Low molecular weight heparin in unstable coronary artery disease. Expert Opinion on Investigational Drugs, 2000, 9, 581-592.	1.9	11
12	Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology Recommendations of the Task Force of the European Society of Cardiology. European Heart Journal, 2000, 21, 1406-1432.	1.0	362
13	Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: Proposed revisions. American Heart Journal, 2000, 139, 461-475.	1.2	57
14	Dalteparin. Drugs, 2000, 60, 203-237.	4.9	21
15	Cardiac markers and risk stratification: an integrated approach. Clinica Chimica Acta, 2001, 311, 9-17.	0.5	15
16	Diagnosis and Risk Stratification in Patients With Acute Coronary Syndromes According to ESC Guidelines. Thrombosis Research, 2001, 103, S57-S61.	0.8	2
18	Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1). Potential risk factor for the acute coronary syndromes. European Heart Journal, 2001, 22, 1226-1234.	1.0	74
19	Instabile Angina pectoris: Management des akuten Koronarsyndroms ohne persistierende ST-Hebungen. Intensivmedizin Und Notfallmedizin, 2001, 38, 257-263.	0.2	6
20	V_alue of First Day Angiography/Angioplasty I_n Evolving N_on-ST Segment Elevation Myocardial Infarction: An O_pen Multicenter Randomized Trial. The VINO Study. European Heart Journal, 2002, 23, 230-238	1.0	153

CITATION REPORT

#	Article	IF	CITATIONS
21	Cost-effectiveness of an invasive strategy in unstable coronary artery disease. Results from the FRISC II invasive trial. European Heart Journal, 2002, 23, 31-40.	1.0	31
22	Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2002, 23, 1809-1840.	1.0	764
23	Current Management of Unstable Angina. American Journal of Cardiovascular Drugs, 2002, 2, 237-243.	1.0	3
24	Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. American Heart Journal, 2002, 143, 753-759.	1.2	172
26	Charles Richard Conti, MD: a conversation with the editor**This series of interviews are underwritten by an unrestricted grant from Bristol-Myers Squibb American Journal of Cardiology, 2002, 89, 726-750.	0.7	0
28	Cardiovascular Risk Factors in the Circadian Rhythm of Acute Myocardial Infarction. Revista Espanola De Cardiologia (English Ed), 2004, 57, 850-858.	0.4	12
29	Management of patients with type 2 diabetes after acute coronary syndromes. Diabetes and Vascular Disease Research, 2005, 2, 144-154.	0.9	7
30	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 2006, 28, 88-136.	1.0	1,144
31	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal Supplements, 2007, 9, C3-C74.	0.0	40
32	GuÃas de práctica clÃnica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. Revista Espanola De Cardiologia, 2007, 60, 525.e1-525.e64.	0.6	13
33	GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES. Rational Pharmacotherapy in Cardiology, 2007, 3, 88-111.	0.3	3
34	Retrospective Analysis of Longâ€ŧerm Lipid Apheresis at a Single Center. Therapeutic Apheresis and Dialysis, 2010, 14, 143-152.	0.4	41
35	Early Clinical Outcomes and Routine Management of Patients With Non–ST-Segment Elevation Myocardial Infarction. Archives of Internal Medicine, 2001, 161, 601.	4.3	16
36	A combination of troponin T and 12-lead electrocardiography: A valuable tool for early prediction of long-term mortality in patients with chest pain without ST-segment elevation. American Heart Journal, 2002, 144, 804-810.	1.2	21
38	The relation between ECG changes and troponin test in patients with non ST segment elevation acute coronary syndrome. Annals of the College of Medicine Mosul, 2013, 39, 12-18.	0.0	0
39	Systemic Inflammatory Response Syndrome Predicts Mortality in Acute Coronary Syndrome without Congestive Heart Failure. Western Journal of Emergency Medicine, 2010, 11, 373-8.	0.6	8